181 related articles for article (PubMed ID: 28885232)
41. Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast.
Perez AA; Balabram D; Rocha RM; da Silva Souza Á; Gobbi H
J Histochem Cytochem; 2015 Jun; 63(6):408-16. PubMed ID: 25711229
[TBL] [Abstract][Full Text] [Related]
42. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases.
Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M
Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215
[TBL] [Abstract][Full Text] [Related]
43. The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading: A Comparative Study With Ki-67 and H&E Mitotic Count.
Khieu ML; Broadwater DR; Aden JK; Coviello JM; Lynch DT; Hall JM
Am J Clin Pathol; 2019 May; 151(6):542-550. PubMed ID: 30788495
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
45. Comparative study of two complementary proliferation markers in 200 breast carcinomas: Ki67 and mitotic index.
El Amine O; Ouni R; Adouni O; Goucha A; Ben Hassouna J; Rahal K; El May A; Gamoudi A
Tunis Med; 2016 Oct; 94(8-9):587-593. PubMed ID: 28685793
[TBL] [Abstract][Full Text] [Related]
46. Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer.
Lee LH; Swanson PE; Tang PA; Bigras G; Yang H
Appl Immunohistochem Mol Morphol; 2017 Jan; 25(1):25-31. PubMed ID: 26371428
[TBL] [Abstract][Full Text] [Related]
47. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
48. Comparative study of two complementary proliferation markers in 200 breast carcinomas: Ki67 and mitotic index.
El Amine O; Ouni R; Adouni O; Goucha A; Ben Hassouna J; Rahal K; El May A; Gamoudi A
Tunis Med; 2016 Oct; 94(10):587-593. PubMed ID: 28972249
[TBL] [Abstract][Full Text] [Related]
49. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.
Williams DJ; Cohen C; Darrow M; Page AJ; Chastain B; Adams AL
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):431-6. PubMed ID: 21297447
[TBL] [Abstract][Full Text] [Related]
50. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.
Aune G; Stunes AK; Tingulstad S; Salvesen O; Syversen U; Torp SH
Int J Clin Exp Pathol; 2011 Jun; 4(5):444-53. PubMed ID: 21738816
[TBL] [Abstract][Full Text] [Related]
51. Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors.
Kim MJ; Kwon MJ; Kang HS; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Park HC
Biomed Res Int; 2018; 2018():1013640. PubMed ID: 29780816
[TBL] [Abstract][Full Text] [Related]
52. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
53. A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms.
Qi G; Liu J; Tao S; Fan W; Zheng H; Wang M; Yang H; Liu Y; Liu H; Zhou F
PeerJ; 2023; 11():e15675. PubMed ID: 37456895
[TBL] [Abstract][Full Text] [Related]
54. Ductal carcinoma in situ and ductal carcinoma in situ with microinvasion: correlation of FDG uptake with histological and biological prognostic factors.
Seo YY; Yoo IR; Park SY; Oh JK; Kim SH; Sohn HS
Breast Cancer; 2017 May; 24(3):353-361. PubMed ID: 27312540
[TBL] [Abstract][Full Text] [Related]
55. The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
Nakamura R; Oyama T; Inokuchi M; Ishikawa S; Hirata M; Kawashima H; Ikeda H; Dobashi Y; Ooi A
Pathol Int; 2020 Jun; 70(6):330-339. PubMed ID: 32103597
[TBL] [Abstract][Full Text] [Related]
56. High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.
Ramani P; Taylor S; Miller E; Sowa-Avugrah E; May MT
J Histochem Cytochem; 2015 Jun; 63(6):397-407. PubMed ID: 25711230
[TBL] [Abstract][Full Text] [Related]
57. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
[TBL] [Abstract][Full Text] [Related]
58. Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast.
Tumedei MM; Silvestrini R; Ravaioli S; Massa I; Maltoni R; Rocca A; Folli S; Buggi F; Curcio A; Serra L; Puccetti M; Amadori D; Bravaccini S
Int J Biol Markers; 2015 Nov; 30(4):e425-8. PubMed ID: 26165687
[TBL] [Abstract][Full Text] [Related]
59. Changes in intrinsic subtype of breast cancer during tumor progression in the same patient.
Kim C; Lee J; Lee W; Kim A
Int J Clin Exp Pathol; 2015; 8(11):15184-90. PubMed ID: 26823864
[TBL] [Abstract][Full Text] [Related]
60. EPIGENETIC CHANGES - HISTONE 3 PHOSPHORYLATION - EPITHELIAL OVARIAN TUMORS.
Munjishvili V; Barabadze E; Muzashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2019 Sep; (294):128-131. PubMed ID: 31687964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
